Ivantis Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$113.6M
Industry:Medical Equip
Lead Investor(s):RA Capital Management

Industry Ranking

Estimated Revenue & Financials

  • Ivantis's estimated annual revenue is currently $18.6M per year.
  • Ivantis received $25.0M in venture funding in January 2017.
  • Ivantis's estimated revenue per employee is $251,000
  • Ivantis's total funding is $113.6M.

Employee Data

  • Ivantis has 74 Employees.
  • Ivantis grew their employee count by 40% last year.
  • Ivantis currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Advertise Here
i-CAT 3D CBCT I...
Medical Guardia...
Titan Spine
Beekley Corpora...
Vernay Laborato...
Planmeca USA
Clinical Innova...
Caldera Medical
Missing a competitor? Contribute!?

Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals


Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Ivantis News

31-Aug-19 - Study Shows MIGS Makes up Nearly Half of Glaucoma ...

There are four FDA-approved MIGS stents: the Glaukos's iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. That number could ...

14-Mar-19 - Ivantis touts 2-year Hydrus, Glaukos iStent head-to-head study ...

Ivantis today released two-year results from a study comparing its Hydrus Microstent to Glaukos' (NYSE:GKOS) iStent trabecular micro-bypass ...

26-Apr-19 - Ivantis and Glaukos Clash in 1st Head-to-Head MIGS Trial

A study accepted for publication in the journal Ophthalmology could give Ivantis a competitive advantage against one of the top players in the ...

Ivantis Funding

DateAmountRoundLead InvestorsReference
2013-02-04$27.0MBAscension Health VenturesArticle
2013-08-21$5.0MBEDBI of SingaporeArticle
2014-09-24$25.0MBForesite CapitalArticle
2017-01-10$25.0MCRA Capital ManagementArticle

Ivantis Acquisitions

DateCompany NameAmountNotesReference
2017-04-13Concorde SolutionsArticle